All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.
